Cargando…
Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
The novel coronavirus, SARS-coronavirus (CoV)-2 (SARS-CoV-2), has caused over 17 million infections in just a few months, with disease manifestations ranging from largely asymptomatic infection to critically severe disease. The remarkable spread and unpredictable disease outcomes continue to challen...
Autores principales: | Loos, Carolin, Atyeo, Caroline, Fischinger, Stephanie, Burke, John, Slein, Matthew D., Streeck, Hendrik, Lauffenburger, Douglas, Ryan, Edward T., Charles, Richelle C., Alter, Galit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471005/ https://www.ncbi.nlm.nih.gov/pubmed/32878931 http://dx.doi.org/10.1128/mSphere.00622-20 |
Ejemplares similares
-
Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
por: Zohar, Tomer, et al.
Publicado: (2020) -
SARS-CoV-2-specific ELISA development
por: Roy, Vicky, et al.
Publicado: (2020) -
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
por: Atyeo, Caroline, et al.
Publicado: (2020) -
Sex differences in vaccine-induced humoral immunity
por: Fischinger, Stephanie, et al.
Publicado: (2018) -
Compromised SARS-CoV-2-specific placental antibody transfer
por: Atyeo, Caroline, et al.
Publicado: (2021)